bromocriptine has been researched along with fluoxetine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chellappan, DK; Collet, TA; Dighe, SN; Dua, K; Ekwudu, O; Katavic, PL | 1 |
| Brooke, D; Fudala, PJ; Johnson, RE | 1 |
| Jackson, DM; Jenkins, OF | 2 |
| Lauterbach, EC | 1 |
| Anton, RF | 1 |
| Bagheri, H; Montastruc, JL; Schmitt, L | 1 |
| de Boissezon, X; de Boysson, C; Démonet, JF; Peran, P | 1 |
| Alam, MS; Ansari, MA; Ashraf, GM; Barkat, MA; Barreto, GE; Javed, MN; Khan, A; Maqbool, A; Nigar, S; Pottoo, FH; Rasheed, R; Tabassum, N | 1 |
| Alam, MS; Ansari, MA; Ashraf, GM; Barkat, MA; Barreto, GE; Javed, MN; Nigar, S; Pottoo, FH; Sharma, S; Tabassum, N | 1 |
6 review(s) available for bromocriptine and fluoxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent update on anti-dengue drug discovery.
Topics: Animals; Antiviral Agents; Biological Products; Cell Line, Tumor; Dengue Virus; Drug Discovery; Humans; Serine Proteinase Inhibitors; Viral Nonstructural Proteins; Virus Replication | 2019 |
Hypothesis: bromocriptine lacks intrinsic dopamine receptor stimulating properties.
Topics: Adenylyl Cyclases; alpha-Methyltyrosine; Animals; Bromocriptine; Desipramine; Dextroamphetamine; Drug Interactions; Fluoxetine; Humans; Methyltyrosines; Mice; Motor Activity; Nialamide; Nomifensine; Nucleus Accumbens; Rats; Receptors, Dopamine; Reserpine; Stereotyped Behavior | 1985 |
Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions.
Topics: Alcoholism; Bromocriptine; Dopamine Agonists; Female; Fluoxetine; Humans; Male; Models, Psychological; Naltrexone; Narcotic Antagonists; Reward; Selective Serotonin Reuptake Inhibitors; Serotonin; Stress Disorders, Post-Traumatic | 1996 |
[Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
Topics: Antidepressive Agents; Antiparkinson Agents; Bromocriptine; Citalopram; Depressive Disorder; Dopamine Agents; Female; Fluoxetine; Gambling; Humans; Levodopa; Middle Aged; Parkinson Disease | 2003 |
Pharmacotherapy of aphasia: myth or reality?
Topics: Amphetamine; Aphasia; Bromocriptine; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dopamine Agents; Fluoxetine; GABA Agonists; Humans; Indans; Neuroprotective Agents; Paroxetine; Physostigmine; Piperidines; Piracetam; Pyridines; Selective Serotonin Reuptake Inhibitors; Serotonin; Stroke; Zolpidem | 2007 |
1 trial(s) available for bromocriptine and fluoxetine
| Article | Year |
|---|---|
Weighing up the pros and cons: help-seeking by drug misusers in Baltimore, USA.
Topics: Adult; Bromocriptine; Buprenorphine; Cocaine; Desipramine; Fear; Female; Fluoxetine; Humans; Male; Methadone; Middle Aged; Motivation; Opioid-Related Disorders; Patient Acceptance of Health Care; Phencyclidine Abuse; Substance Abuse Treatment Centers; Substance-Related Disorders; Urban Population | 1992 |
8 other study(ies) available for bromocriptine and fluoxetine
| Article | Year |
|---|---|
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Bromocriptine potentiates the behavioural effects of directly and indirectly acting dopamine receptor agonists in mice.
Topics: alpha-Methyltyrosine; Animals; Bromocriptine; Desipramine; Drug Synergism; Fluoxetine; Haloperidol; Levodopa; Male; Methyltyrosines; Mice; Motor Activity; Nomifensine; Receptors, Dopamine; Reserpine | 1985 |
Dopaminergic hallucinosis with fluoxetine in Parkinson's disease.
Topics: Aged; Bromocriptine; Carbidopa; Fluoxetine; Hallucinations; Humans; Levodopa; Male; Parkinson Disease; Visual Perception | 1993 |
The Synergistic Effect of Raloxifene, Fluoxetine, and Bromocriptine Protects Against Pilocarpine-Induced Status Epilepticus and Temporal Lobe Epilepsy.
Topics: Animals; Anticonvulsants; Bromocriptine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Epilepsy, Temporal Lobe; Female; Fluoxetine; Hippocampus; Male; Mice; Neurons; Oxidative Stress; Pilocarpine; Raloxifene Hydrochloride; Status Epilepticus | 2019 |
Raloxifene potentiates the effect of fluoxetine against maximal electroshock induced seizures in mice.
Topics: Animals; Anticonvulsants; Bromocriptine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Electroshock; Fluoxetine; Glutamic Acid; Hippocampus; Mice; Neuropeptide Y; Oxidative Stress; Raloxifene Hydrochloride; Receptors, Dopamine; Receptors, Serotonin; Seizures; Signal Transduction | 2020 |